Sugi Predict

Sugi Predict / Compounds / SCHEMBL1546090

SCHEMBL1546090

SCHEMBL1546090

Cc1cc(Nc2nc(Nc3ccccc3S(=O)(=O)C(C)C)c3ccccc3n2)c(OC(C)C)cc1C1CCN(C)CC1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALK Q9UM73 20/20 1.00
▸ INSR P06213 17/20 1.00
▸ NPM1 P06748 13/20 1.00
▸ KCNH2 Q12809 6/20 0.80
▸ CYP3A4 P08684 3/20 0.80
▸ ABL1 P00519 1/20 0.73
▸ EGFR P00533 1/20 0.73
▸ ERBB2 P04626 1/20 0.73
▸ LCK P06239 1/20 0.73
▸ RET P07949 1/20 0.73
▸ IGF1R P08069 1/20 0.73
▸ MET P08581 1/20 0.73
▸ PDGFRA P16234 1/20 0.73
▸ CDK2 P24941 1/20 0.73
▸ AKT1 P31749 1/20 0.73
▸ KDR P35968 1/20 0.73
▸ GSK3B P49841 1/20 0.73
▸ PLK1 P53350 1/20 0.73
▸ EPHB4 P54760 1/20 0.73
▸ BTK Q06187 1/20 0.73

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12388974 0.93 ALK (0.87) ALKINSRNPM1KCNH2CYP3A4
SCHEMBL1546108 0.91 ALK (1.00) ALKINSRNPM1KCNH2CYP3A4
SCHEMBL1546071 0.91 ALK (0.84) ALKINSRNPM1KCNH2CYP3A4
SCHEMBL21099671 0.89 ALK (0.80) ALKINSRNPM1KCNH2CYP3A4
SCHEMBL1952646 0.89 ALK (1.00) ALKINSRNPM1KCNH2CYP3A4
SCHEMBL12213956 0.89 ALK (1.00) ALKINSRNPM1KCNH2CYP3A4
SCHEMBL19921216 0.89 ALK (0.80) ALKINSRNPM1KCNH2CYP3A4
SCHEMBL14110148 0.89 ALK (0.80) ALKINSRNPM1KCNH2CYP3A4
SCHEMBL1949497 0.88 ALK (0.79) ALKINSRNPM1KCNH2CYP3A4
SCHEMBL1545609 0.88 ALK (1.00) ALKINSRNPM1KCNH2CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3012249-A1 COMPOUNDS AND COMPOSITION AS PROTEIN KINASE INHIBITORS Novartis AG (CH) 2016-04-27 — — EP claimed
EP-2311807-B1 Compounds and composition as protein kinase inhibitors NOVARTIS AG (CH) 2015-11-11 — — EP claimed
EP-2311807-A1 Compounds and composition as protein kinase inhibitors IRM LLC (BM) 2011-04-20 — — EP claimed
EP-3012249-A1 COMPOUNDS AND COMPOSITION AS PROTEIN KINASE INHIBITORS Novartis AG (CH) 2016-04-27 — — EP disclosed
EP-3012249-A1 COMPOUNDS AND COMPOSITION AS PROTEIN KINASE INHIBITORS Novartis AG (CH) 2016-04-27 — — EP disclosed
EP-2311807-B1 Compounds and composition as protein kinase inhibitors NOVARTIS AG (CH) 2015-11-11 — — EP disclosed
EP-2311807-B1 Compounds and composition as protein kinase inhibitors NOVARTIS AG (CH) 2015-11-11 — — EP disclosed
US-20150105390-A1 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS IRM LLC, A DELAWARE LIMITED LIABILITY COMPANY (BM) 2015-04-16 — — US disclosed
US-20150105390-A1 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS IRM LLC, A DELAWARE LIMITED LIABILITY COMPANY (BM) 2015-04-16 — — US disclosed
US-20150105390-A1 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS IRM LLC, A DELAWARE LIMITED LIABILITY COMPANY (BM) 2015-04-16 — — US disclosed
US-8957081-B2 Compounds and compositions as protein kinase inhibitors IRM LLC (BM) 2015-02-17 — — US disclosed
US-8039479-B2 Such as 6-{5-Chloro-4-[2-(propane-2-sulfonyl)-phenylamino]-pyrimidin-2-ylamino}-5-isopropoxy-2-piperidin-4-yl-2,3-dihydro-isoindol-1-one; tumors, cancer; inhibition of anaplastic lymphoma, focal adhesion, zeta chain associated protein 70 and/or insulin like growth factor IRM LLC (BM) 2011-10-18 — — US disclosed
US-20110190259-A1 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS IRM LLC (BM) 2011-08-04 — — US disclosed
US-20110190259-A1 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS IRM LLC (BM) 2011-08-04 — — US disclosed
EP-2311807-A1 Compounds and composition as protein kinase inhibitors IRM LLC (BM) 2011-04-20 — — EP disclosed
EP-2311807-A1 Compounds and composition as protein kinase inhibitors IRM LLC (BM) 2011-04-20 — — EP disclosed
US-20080176881-A1 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS IRM LLC (BM) 2008-07-24 — — US disclosed
US-20080176881-A1 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS IRM LLC (BM) 2008-07-24 — — US disclosed
US-20080176881-A1 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS IRM LLC (BM) 2008-07-24 — — US disclosed
WO-2008073687-A2 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS IRM LLC (BM) 2008-06-19 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080176881-A1 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS ZAP70, IGF1R, PTK2 ALK 23/4885INSR 67/4885NPM1 2242/4885
US-20110190259-A1 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS ZAP70, IGF1R, PTK2 ALK 23/4885INSR 67/4885NPM1 2242/4885
US-20150105390-A1 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS ZAP70, IGF1R, PTK2 ALK 23/4885INSR 67/4885NPM1 2242/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback